

Attendees

ISPOR 46th HTA Roundtable [Middle East and Africa]

Wednesday, 25 September 2019 - 14:30 - 17:30

(Training on MCDA, Room: Capital Suite 5)

Thursday, 26 September 2019 - 08:30 - 12:30

(HTA Roundtable, Room: Capital Suite 3) **Abu Dhabi National Exhibition Centre**

Abu Dhabi, United Arab Emirates

<u>Jordan</u>

Abeer A. Al-Rabayah, MBA, MSc, BScPharm

Head, Center for Drug Policy & Technology Assessment (CDPTA), Department of Pharmacy

King Hussein Cancer Center

Amman, Jordan

Kuwait

Mai Alhazami, PhD

Assistant Professor, School of Pharmacy

Kuwait University

Yarmook, Kuwait

<u>Oman</u>

Manal Al Ansari, MSc

Director, Rationale Use of Medicines

Ministry of Health

Muscat, Oman

Saudi Arabia

Abdulaziz Al-Saggabi, PharmD, MSc

Director, Drug Policy & Economics Center

Ministry of National Guard Health Affairs

Riyadh, Saudi Arabia

Tunisia

Sondes Hamida, MSc

Head, Medicine Control

Caisse Nationale d'Assurance Maladie de Tunisie (CNAM)

Tunis, Tunisia



Attendees

Mouna Jameleddine, PharmD, MSc

Director, HTA Department, Instance Nationale de l'Evaluation & de l'Accréditation en Santé (INEAS)

Board Member, The International Network of Agencies for Health Technology Assessment (INAHTA)

Tunis, Tunisia

United Arab Emirates

Ola Ghaleb Ahmad Al Ahdab, PhD, RPh

Pharmaceutical Advisor, Registration and Drug Control Department

Ministry of Health

Abu Dhabi, United Arab Emirates

Invited Speaker

Meindert Boysen, PharmD, MSc

Director, Centre for Health Technology Evaluation

National Institute for Health and Clinical Excellence (NICE)

Manchester, England, United Kingdom

Zoltán Kaló, PhD

Professor of Health Economics, Center for Health Technology Assessment, **Semmelweis University**

CEO, Syreon Research Institute

Budapest, Hungary

ISPOR Staff

Nadia Naaman, Senior Director, Scientific and Health Policy Initiatives